US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zenas BioPharma Inc.

9.75

+0.83009.30%

Volume:181.04K

Turnover:1.69M

Market Cap:407.54M

PE:-0.82

High:9.86

Open:8.74

Low:8.55

Close:8.92

Loading ...

Overview Company News Filings

Zenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP Before June 16, 2025 to Discuss Your Rights – ZBIO

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma appoints Haley Laken as CSO

Zenas Biopharma Appoints Haley Laken, Ph.d., as Chief Scientific Officer

THOMSON REUTERS

Press Release: Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

Zenas BioPharma Initiated at Outperform by Wedbush

Wedbush Initiates Zenas BioPharma at Outperform With $35 Price Target

MT Newswires Live

Zenas BioPharma initiated with an Outperform at Wedbush

Zenas Biopharma Appoints Lisa Von Moltke, M.d., as Head of Research and Development and Chief Medical Officer

THOMSON REUTERS

Press Release: Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?

Simply Wall St.

Director Makes Bold Move with Major Stock Purchase in Zenas BioPharma!

BRIEF-Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives

Zenas Biopharma- Cash Equivalents, Short-Term Investments as of Dec 31 to Fund Operating Expenses & Capex Requirements Into Q4 2026

THOMSON REUTERS

Zenas Biopharma :Topline Results From Pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (Indigo) Expected Year-End 2025

THOMSON REUTERS

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

Zenas BioPharma Initiated at Outperform by Wolfe Research

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ZBIO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":9.75,"timestamp":1745265600000,"preClose":8.92,"halted":0,"volume":181036,"delay":0,"floatShares":20878693,"shares":41799336,"eps":-11.893967,"marketStatus":"Pre-Mkt","change":0.83,"latestTime":"04-22 04:30:22 EDT","open":8.74,"high":9.855,"low":8.55,"amount":1692505.3829639999,"amplitude":0.1463,"askPrice":11.61,"askSize":100,"bidPrice":8.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-11.893967,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":9.75,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":9.75,"preClose":9.75,"latestTime":"19:55 EDT","volume":462,"amount":4514.04,"timestamp":1745279724267},"volumeRatio":1.1726952388930805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":20878693,"roa":"-46.76%","roe":"-93.22%","lyrEps":-11.893967,"volumeRatio":1.1726952388930805,"shares":41799336,"dividePrice":0.04783,"high":9.855,"amplitude":0.1463,"preClose":8.92,"low":8.55,"week52Low":5.83,"pbRate":"1.30","psRate":"81.51","week52High":26.2508,"institutionHeld":0,"latestPrice":9.75,"eps":-11.893967,"divideRate":0.004906,"volume":181036,"delay":0,"ttmEps":-11.893967,"open":8.74,"prevYearClose":8.19,"prevWeekClose":8.92,"prevMonthClose":7.9,"prevQuarterClose":7.9,"fiveDayClose":7.93,"twentyDayClose":8.33,"sixtyDayClose":8.38},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528779147","title":"Zenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP Before June 16, 2025 to Discuss Your Rights – ZBIO","url":"https://stock-news.laohu8.com/highlight/detail?id=2528779147","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528779147?lang=en_us&edition=fundamental","pubTime":"2025-04-18 05:05","pubTimestamp":1744923903,"startTime":"0","endTime":"0","summary":"THE LAWSUIT: This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/zenas-biopharma-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-llp-before-june-16-2025-to-discuss-your-rights-zbio?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/zenas-biopharma-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-llp-before-june-16-2025-to-discuss-your-rights-zbio?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","ZBIO","BK4211","BK4139"],"gpt_icon":0},{"id":"2528713773","title":"Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2528713773","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528713773?lang=en_us&edition=fundamental","pubTime":"2025-04-18 04:20","pubTimestamp":1744921232,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA1TY5YB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2528084774","title":"Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2528084774","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528084774?lang=en_us&edition=fundamental","pubTime":"2025-04-18 04:20","pubTimestamp":1744921200,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April 17, 2025  -- Zenas BioPharma, Inc.  , a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 , the Compensation Committee of the Company’s Board of Directors  granted non-qualified stock options to two newly hired officers of the Company, each as an inducement material to each officer’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635.The Committee granted a non-qualified stock option to purchase 400,000 shares of the Company’s common stock to Lisa von Moltke, M.D., who was recently appointed to the role of Head of Research and Development and Chief Medical Officer . In addition, the Committee granted a non-qualified stock option to purchase 250,000 shares of the Company’s common stock to Haley Laken, Ph.D., the Company’s new Chief Scientific Officer .The Zenas BioPharma word mark, logo mark","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zenas-biopharma-announces-inducement-grants-202000706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","QLD","NVIW.SI","LU2095319765.USD","USJW.SI","MNQmain","IE00B3QW5Z07.USD","ZBIO","NQmain","BK4588","TQQQ","BK4112","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","LU2210150020.SGD","TSYW.SI","NDAQ","BK4139","QID","IE00BKPKM429.USD","IE00BGHQF748.EUR","USAW.SI","PSQ",".IXIC"],"gpt_icon":1},{"id":"2525148720","title":"Zenas BioPharma appoints Haley Laken as CSO","url":"https://stock-news.laohu8.com/highlight/detail?id=2525148720","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525148720?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:15","pubTimestamp":1744024523,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO) announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer. Prior to joining Zenas, Dr. Laken served as CO...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-appoints-haley-laken-as-cso?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-appoints-haley-laken-as-cso?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2525197040","title":"Zenas Biopharma Appoints Haley Laken, Ph.d., as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2525197040","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525197040?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:05","pubTimestamp":1744023900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nTUAB23FCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2525019072","title":"Press Release: Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2525019072","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525019072?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:05","pubTimestamp":1744023900,"startTime":"0","endTime":"0","summary":"Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategy. WALTHAM, Mass., April 07, 2025  -- Zenas BioPharma, Inc.  , a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer . Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development.Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candida","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2521037934","title":"North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2521037934","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521037934?lang=en_us&edition=fundamental","pubTime":"2025-03-21 18:02","pubTimestamp":1742551320,"startTime":"0","endTime":"0","summary":"The euphoria from the Federal Reserve's policy meeting didn't last long.Stock futures were lower Friday as attention shifted from the Fed to the prospect of further tariffs.Trump said in a social media post that the planned imposition of reciprocal tariffs on April 2 would be \"Liberation Day\" in the U.S.\"We maintain our view that the FOMC outcome was effectively a one-day move, with minimal legacy in terms of immediate direction. That said, we also view the FOMC outcome as a whole as nodding towards dovishness, but with numerous caveats,\" ING said.Quantum-computing stocks  are likely to be in focus after suffering steep falls on Thursday as investors appeared unimpressed by their contributions to Nvidia's Quantum Day at its GTC developers' event.The market also faces a test as an estimated $4.5 trillion in options contracts expire, which could increase volatility.FedEx fell 5.1% off hours after it cut its outlook for the year.Lennar management warned investors of a weak housing market.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["US10Y.BOND","IRD","NVDD","FBLG","IMRX","USAU","XOMA","US30Y.BOND","ET","NVDS.UK","US2Y.BOND","US7Y.BOND","DXYN","DM","ADVM","NVDY","SNVD.UK","SMXT","NGNE","CCL","NVDL","GORV","US6M.BOND","JVA","BPTH","US3Y.BOND","PURE","FBRX","US5Y.BOND","3NVD.UK","BOLD","AFG","NVDU","2NVD.UK","MPU","US12M.BOND","NVD3.UK","NVIW.SI","OLMA","NVDS","IMNM","PRPH","NVDA","ATXI","NVD2.UK","ZBIO","CKPT","SGMA","NVDX"],"gpt_icon":1},{"id":"2521849599","title":"Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2521849599","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521849599?lang=en_us&edition=fundamental","pubTime":"2025-03-21 02:54","pubTimestamp":1742496883,"startTime":"0","endTime":"0","summary":"On Thursday, Wedbush initiated coverage on Zenas BioPharma, Inc. , a clinical-stage global biopharmaceutical company focused on developing therapies for autoimmune disease.Zenas BioPharma started trading on the NASDAQ in September 2024. The company closed an upsized initial public offering of 15.22 million shares at $17 per share, raising approximately $258.7 million in gross proceeds.The company’s lead program obexelimab concluded enrollment in the Phase 3 INDIGO trial for immunoglobulin-G4-Related Disease . Topline data is expected by the end of 2025.The company also initiated the Phase 2 MoonStone trial for Relapsing Multiple Sclerosis  and the Phase 2 SunStone trial for Systemic Lupus Erythematosus .Wedbush initiated coverage with an outperform rating and a price forecast of $35.Analyst Fan writes that the unique safety feature is especially important for conditions like IgG4-RD, MS, and SLE, where long-term safety and immune protection influence treatment decisions.This article Ze","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zenas-biopharma-gains-outperform-rating-185443725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZBIO","PRGS"],"gpt_icon":0},{"id":"2520453743","title":"Zenas BioPharma Initiated at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2520453743","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520453743?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:05","pubTimestamp":1742472300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 08:05 ET (12:05 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0},{"id":"2520143224","title":"Wedbush Initiates Zenas BioPharma at Outperform With $35 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2520143224","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520143224?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:56","pubTimestamp":1742468161,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO) has an average rating of buy and mean price target of $33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO"],"gpt_icon":0},{"id":"2520651437","title":"Zenas BioPharma initiated with an Outperform at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2520651437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520651437?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:55","pubTimestamp":1742468147,"startTime":"0","endTime":"0","summary":"Wedbush initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $35 price target Published first on TheFly – the ultimate source...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-initiated-with-an-outperform-at-wedbush?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-initiated-with-an-outperform-at-wedbush?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"gpt_icon":0},{"id":"2520549984","title":"Zenas Biopharma Appoints Lisa Von Moltke, M.d., as Head of Research and Development and Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520549984","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520549984?lang=en_us&edition=fundamental","pubTime":"2025-03-17 19:05","pubTimestamp":1742209500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nTUA2SXT6X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2520499695","title":"Press Release: Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520499695","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520499695?lang=en_us&edition=fundamental","pubTime":"2025-03-17 19:05","pubTimestamp":1742209500,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer. --Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies--. Dr. von Moltke most recently served as CMO at Seres Therapeutics with functional oversight of clinical development, sciences and operations, and regulatory and medical affairs. Prior to Seres, Dr. von Moltke served in roles of increasing responsibility at Alkermes, Inc., culminating as Senior Vice President and Head of Clinical Development. Before joining Alkermes, Dr. von Moltke was Vice President, Clinical and Exploratory Pharmacology at Sanofi/Genzyme Corporation, where she also served as U.S. Head Clinical & Exploratory Pharmacology Sciences  and Early Development and later as Head of CEP for Japan and China. Earlier in her career, Dr. von Moltke was Head, Translational","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","CEP","BK4139"],"gpt_icon":0},{"id":"2519833894","title":"Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519833894","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519833894?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:27","pubTimestamp":1741865272,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?So, the natural question for Zenas BioPharma  shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth . We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.Since it has a market capitalisation of US$303m, Zenas BioPharma's US$120m in cash burn equates to about 40% of its market value. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zenas-biopharma-nasdaq-zbio-good-112752658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","USJW.SI","BK4139","TSYW.SI","LU2210150020.SGD","NVIW.SI","ZBIO","IE00BGHQF748.EUR","USAW.SI","SQQQ","NDAQ","QID","BK4112","BK4585","IE00B3QW5Z07.USD","TQQQ","QLD","IE00B64PRP62.GBP","MNQmain","LU2210149790.SGD","NQmain","IE00BKPKM429.USD","PSQ","BK4588",".IXIC"],"gpt_icon":1},{"id":"2510993343","title":"Director Makes Bold Move with Major Stock Purchase in Zenas BioPharma!","url":"https://stock-news.laohu8.com/highlight/detail?id=2510993343","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510993343?lang=en_us&edition=fundamental","pubTime":"2025-02-12 10:02","pubTimestamp":1739325772,"startTime":"0","endTime":"0","summary":"New insider activity at Zenas BioPharma, Inc. ( ($ZBIO) ) has taken place on February 12, 2025. Director Ting Xiao has made a significant investmen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-stock-purchase-in-zenas-biopharma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-stock-purchase-in-zenas-biopharma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2509004414","title":"BRIEF-Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2509004414","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509004414?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:36","pubTimestamp":1738759009,"startTime":"0","endTime":"0","summary":"BRIEF-Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives Feb 5 (Reuters) - Zenas Biopharma Inc ZBIO.O:ZENAS BIOPHARMA : TOPLINE RESULTS FROM PHASE 2 TRIAL IN RELAPSING MUL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW195:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2509840786","title":"Zenas Biopharma- Cash Equivalents, Short-Term Investments as of Dec 31 to Fund Operating Expenses & Capex Requirements Into Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2509840786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509840786?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:09","pubTimestamp":1738757393,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW0Y0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2509407893","title":"Zenas Biopharma :Topline Results From Pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (Indigo) Expected Year-End 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509407893?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:08","pubTimestamp":1738757333,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW195:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2509407986","title":"Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407986","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509407986?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:05","pubTimestamp":1738757100,"startTime":"0","endTime":"0","summary":"- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/05/3021061/0/en/Zenas-BioPharma-Announces-Key-2024-Accomplishments-and-2025-Business-Objectives-to-Support-the-Global-Development-and-Commercialization-of-Therapies-for-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","BK4139","ZBIO"],"gpt_icon":0},{"id":"2508026459","title":"Zenas BioPharma Initiated at Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2508026459","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508026459?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:26","pubTimestamp":1738675560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 04, 2025 08:26 ET (13:26 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2024/09","expectedEps":13,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-5.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.7143,"buy":0.2857,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.7143,"analysts":7,"updateTime":1742702400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2025-04-17","current":-2.21793,"percent":0.831081,"low":-19.592941,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"high":-1.802568,"avg":-6.151197,"sd":5.453232,"marketCap":348188468},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468}],"updateTime":1745273648653}}}